Camrelizumab Plus CAPOX Improves Survival in Gastric Cancer
Phase 3 trial shows camrelizumab plus CAPOX with maintenance therapy significantly improves overall survival vs CAPOX alone in HER2-negative gastric cancer.
CAPOX
1 article tagged "CAPOX"
1 article tagged "CAPOX"
Phase 3 trial shows camrelizumab plus CAPOX with maintenance therapy significantly improves overall survival vs CAPOX alone in HER2-negative gastric cancer.